Manjinder Kaur, DO
Endocrinology, Diabetes & Metabolism · Hudson, OHNPI 1487865309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,735 of the $57,772 with a category attached, or 86.1%. Lilly USA, LLC accounts for 81.4% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $39,863, more than ten times the $329 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $238.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$47K
- Novo Nordisk$9K
- BETA Bionics, Inc.$244
- Corcept Therapeutics$204
- Ascendis Pharma Endocrinology Inc$196
- Dexcom, Inc.$191
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$49,73586%
- Travel & lodging$1,9263%
- Food & beverage$6,08711%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 101 | $47,000 |
| Novo Nordisk | 47 | $8,851 |
| BETA Bionics, Inc. | 2 | $244 |
| Corcept Therapeutics | 8 | $204 |
| Ascendis Pharma Endocrinology Inc | 6 | $196 |
| Dexcom, Inc. | 16 | $191 |
| Medtronic(2 entities) | 8 | $145 |
| Abbott | 7 | $127 |
| Amgen | 5 | $91 |
| AbbVie | 3 | $86 |
| Tandem Diabetes Care, Inc. | 6 | $82 |
| Esperion Therapeutics, Inc. | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 4 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Radius Health, Inc. | 3 | $53 |
| AstraZeneca(2 entities) | 2 | $33 |
| Insulet Corporation | 2 | $33 |
| Vivus LLC | 2 | $32 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Novartis | 1 | $18 |
| Dermira, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Cequr Corporation | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$44,058
- Wegovy$7,965
- iLet Bionic Pancreas$676
- MOUNJARO$322
How this compares
$57,772 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $279,153 |
| MounjaroTirzepatide | 74 | $95,356 |
| JardianceEmpagliflozin | 55 | $58,278 |
| TrulicityDulaglutide | 37 | $46,896 |
| JanuviaSitagliptin Phosphate | 36 | $34,463 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $21,960 |
| TradjentaLinagliptin | 25 | $20,040 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $16,760 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $9,661 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,574 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $8,978 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 50 | $5,646 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,198 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $4,833 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $3,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $8,851 | $279,153246 claims |
| Lilly USA, LLCMounjaro, Trulicity | $47,000 | $142,252111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $78,31780 claims |
| AbbVieSynthroid | $86 | $3,36936 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,576240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Hudson
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
- Shawn PeavieCincinnati$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.